Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 7 | 1 |
| List of Figures | 7 | 1 |
| Lead Discovery Center GmbH Snapshot | 8 | 1 |
| Lead Discovery Center GmbH Overview | 8 | 1 |
| Key Information | 8 | 1 |
| Key Facts | 8 | 1 |
| Lead Discovery Center GmbH Research and Development Overview | 9 | 4 |
| Key Therapeutic Areas | 9 | 4 |
| Lead Discovery Center GmbH Pipeline Review | 13 | 6 |
| Pipeline Products by Stage of Development | 13 | 1 |
| Pipeline Products Monotherapy | 14 | 1 |
| Pipeline Products Partnered Products | 15 | 1 |
| Partnered Products/Combination Treatment Modalities | 16 | 1 |
| Pipeline Products Out-Licensed Products | 17 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 18 | 1 |
| Lead Discovery Center GmbH Pipeline Products Glance | 19 | 3 |
| Lead Discovery Center GmbH Early Stage Pipeline Products | 19 | 1 |
| Preclinical Products/Combination Treatment Modalities | 19 | 1 |
| Discovery Products/Combination Treatment Modalities | 20 | 2 |
| Lead Discovery Center GmbH Drug Profiles | 22 | 45 |
| Small Molecule for Target RhoGEF12 for Cardiovascular Disease | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| Small Molecule to Activate Beclin1 for Neurodegenerative Diseases and Viral Infections | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| Small Molecules to Antagonize RON Kinase for Oncology | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| Small Molecules to Inhibit Cyclophilin for Immunology and Respiratory Disorders | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| englerin A | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| Small Molecule 1 for Oncology | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| Small Molecule 2 for Oncology | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| Small Molecule 3 for Oncology | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| Small Molecule 4 for Oncology | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| Small Molecule for AMD, Inflammation and Oncology | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| Small Molecule for Amyotrophic Lateral Sclerosis | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| Small Molecule for Chlamydia Infections | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| Small molecule for Multiple Sclerosis | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Small Molecule for Oncology | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| Small Molecule to Activate TRIM32 for Neurodegenerative Diseases | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Small Molecule to Agonize P2Y6R for Type 2 Diabetes | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Small Molecule to Block TRPC4 and TRPC5 for Cardiovascular Disease and Epilepsy | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| Small Molecule to Inhibit AML1/ETO for Acute Myeloid Leukemia | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| Small Molecule to Inhibit CDK12 and CDK13 for Oncology | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Small Molecule to Inhibit Chemerin for Inflammation | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| Small Molecule to Inhibit degS Serine Endoprotease for Bacterial Infections | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| Small Molecule to Inhibit GLUT1 for Oncology | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| Small Molecule to Inhibit GRK5 for Type 2 Diabetes | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| Small Molecule to Inhibit MARK2 for Alzheimer's Disease | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| Small Molecule to Inhibit Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 1 |
| Small Molecule to Inhibit RabGGTase for Solid Tumors | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 1 |
| Small Molecule to Inhibit SFRP1 for Oncology | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 1 |
| Small Molecule to Inhibit Steroid Sulfatase for Oncology | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| Small Molecule to Target Draxin for Oncology | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 1 |
| Small Molecule to Target Hedgehog Pathway for Oncology | 52 | 1 |
| Product Description | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| R&D Progress | 52 | 1 |
| Small Molecule to Target K-Ras/PDE Delta for Oncology | 53 | 1 |
| Product Description | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| R&D Progress | 53 | 1 |
| Small Molecule to Target Nrg1-ErbB4 Pathway for Schizophrenia and Cardiovascular Diseases | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| Small Molecule to Target SLC6A15 for Major Depressive Disorder | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| Small Molecules 1 for Oncology | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| Small Molecules for Charcot-Marie-Tooth Disease Type I A | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 1 |
| Small Molecules for Influenza | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 1 |
| Small Molecules for Lung Cancer | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| Small Molecules for Oncology | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 1 |
| Small Molecules to Activate GFAT for Alzheimer s Disease | 61 | 1 |
| Product Description | 61 | 1 |
| Mechanism of Action | 61 | 1 |
| R&D Progress | 61 | 1 |
| Small Molecules to Agonize GPR81 for Atherosclerosis and Obesity | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| Small Molecules to Inhibit LRRK2 for Parkinson's Disease | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| Small Molecules to Inhibit NET Formation for Sepsis and SLE | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 1 |
| Small Molecules to Target Notch Signaling Pathway for Oncology | 65 | 1 |
| Product Description | 65 | 1 |
| Mechanism of Action | 65 | 1 |
| R&D Progress | 65 | 1 |
| Small Molecules to Target SIRT7 for Cardiovacular Diseases, Metabolic Syndrome and Oncology | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 1 |
| Lead Discovery Center GmbH Pipeline Analysis | 67 | 5 |
| Lead Discovery Center GmbH Pipeline Products by Target | 67 | 2 |
| Lead Discovery Center GmbH Pipeline Products by Molecule Type | 69 | 1 |
| Lead Discovery Center GmbH Pipeline Products by Mechanism of Action | 70 | 2 |
| Lead Discovery Center GmbH Recent Pipeline Updates | 72 | 1 |
| Lead Discovery Center GmbH Dormant Projects | 73 | 1 |
| Lead Discovery Center GmbH Locations And Subsidiaries | 74 | 1 |
| Head Office | 74 | 1 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |